Provided by Tiger Trade Technology Pte. Ltd.

Ironwood Pharmaceuticals

4.29
+0.15003.62%
Pre-market: 4.370.0800+1.86%05:35 EDT
Volume:2.27M
Turnover:9.70M
Market Cap:706.19M
PE:5.44
High:4.30
Open:4.22
Low:4.19
Close:4.14
52wk High:5.78
52wk Low:1.01
Shares:164.61M
Float Shares:136.00M
Volume Ratio:1.41
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7890
EPS(LYR):0.1484
ROE:-574.72%
ROA:47.02%
PB:-4.36
PE(LYR):28.91

Loading ...

Ironwood repays $200 million 1.5% convertible notes at maturity

Reuters
·
Jun 16

Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026

TIPRANKS
·
Jun 02

Ironwood Pharma to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 29

FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation

Reuters
·
May 27

FDA approves Ironwood’s Linzess for functional constipation in children aged 2 and older

Reuters
·
May 27

Ironwood Pharmaceuticals - Linzess Contraindicated in Patients Under 2 Years Due to Risk of Serious Dehydration

THOMSON REUTERS
·
May 27

Ironwood Pharmaceuticals Inc: Linzess Is Contraindicated in Patients With Known or Suspected Mechanical Gastrointestinal Obstruction

THOMSON REUTERS
·
May 27

FDA Approves Use of Linzess® (Linaclotide) in Pediatric Patients Two Years of Age and Older With Functional Constipation (Fc)

THOMSON REUTERS
·
May 27

Ironwood amends 8-K to disclose interim CFO Ronald Silver’s $12,250 monthly fee

Reuters
·
May 22

Kyverna names Greg Martini CFO, succeeding Marc Grasso

Reuters
·
May 18

Ironwood CFO Gregory Martini resigns, Ronald Silver named interim CFO

Reuters
·
May 13

Ironwood Pharmaceuticals Inc - Appoints Ronald Silver as Interim CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 13

Ironwood Pharmaceuticals Inc - Gregory Martini Resigns as CFO Effective May 15, 2026 - SEC Filing

THOMSON REUTERS
·
May 13

Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Ironwood Q1 revenue jumps 159%, beats analyst expectations

Reuters
·
May 07

BRIEF-Ironwood Pharmaceuticals Q1 Revenue USD 106.506 Million Vs. IBES Estimate USD 92.1 Million

Reuters
·
May 07

Ironwood Pharmaceuticals Inc - Sees 2026 U.S. Linzess Net Sales $1.125-$1.175 Bln

THOMSON REUTERS
·
May 07

Ironwood Pharmaceuticals Q1 Basic EPS USD 0.25

THOMSON REUTERS
·
May 07

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year Linzess U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

THOMSON REUTERS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06